Endo International plc

305 articles about Endo International plc

• Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

  1/13/2022

  Endo International plc (NASDAQ:ENDP) announced today the publication of data from a population pharmacokinetic (PK) modeling and simulation study, evaluating potential dosing flexibility of AVEED® (testosterone undecanoate) in hypogonadal males.

• Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development

  1/11/2022

  Endo International plc (NASDAQ: ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18 , 2022. 

• Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution

  1/4/2022

  Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the first generic version of Merz's CUVPOSA® 1 mg/5 mL oral solution in the U.S., following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

• Endo to Participate at J.P. Morgan 40th Annual Healthcare Conference

  1/4/2022

  Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 a.m. EST.

• Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada

  12/23/2021

  Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with SK Biopharmaceuticals for the development, registration, supply, commercialization and distribution of cenobamate on an exclusive basis in Canada. 

• Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

  11/22/2021

  Endo International plc (NASDAQ:ENDP) announced today that data from clinical and non-clinical studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes) were presented during the annual meeting of the American Society for Dermatologic Surgery (ASDS).

• Endo Begins Shipment of Generic MIACALCIN® (calcitonin salmon) Injection

  11/18/2021

  Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping calcitonin salmon injection, USP, multi-dose vials (2 mL) following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

• Endo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care

  11/8/2021

   Endo International plc (NASDAQ: ENDP) today announced that its Par Sterile Products business will supply VASOSTRICT ® , vasopressin injection, USP, vial presentations to healthcare providers through Premier's Premier ProRx ® program

• Endo Reports Third-Quarter 2021 Financial Results And Raises 2021 Financial Guidance

  11/4/2021

   Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2021.

• Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting

  10/22/2021

  Endo International plc (NASDAQ: ENDP) announced today that new post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH) in treating men with Peyronie's disease (PD) will be presented today in an oral presentation during the Sexual Medicine Society of North America (SMSNA) annual meeting.

• Endo to Announce Third Quarter 2021 Financial Results

  10/5/2021

  Endo International plc (NASDAQ: ENDP) will announce its third–quarter 2021 financial results on November 4, 2021 and members of its senior management team will host a conference call and webcast on November 5, 2021 at 7:30am ET before the U.S. financial markets open.

• Endo Presents New Investigational Collagenase Clostridium Histolyticum (CCH) Survey Data at American Society for Surgery of the Hand (ASSH) Annual Meeting

  9/30/2021

  Endo International plc (NASDAQ: ENDP) today announced results from the first two rounds of Delphi research exploring the expert positions of hand surgeons on the appropriate treatment of Dupuytren's disease (DD) with collagenase clostridium histolyticum (CCH) in patients with varying degrees of disease severity and functional impairment.

• Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation

  8/31/2021

   Endo International plc ("Endo") (NASDAQ: ENDP) today commented on the United States District Court for the District of Delaware's non-infringement ruling in favor of Eagle Pharmaceuticals Inc.

• Endo Reports Second-Quarter 2021 Financial Results And Updates 2021 Financial Guidance

  8/5/2021

  Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2021.

• Endo Presents New Investigational Collagenase Clostridium Histolyticum Data at the American Podiatric Medical Association Annual Scientific Meeting

  7/29/2021

  Endo International plc (NASDAQ:ENDP) announced today initial results from a Phase I study (EN3835–105) evaluating collagenase clostridium histolyticum (CCH) for the treatment of plantar fibromatosis.

• Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at Cosmetic Bootcamp 2021

  6/24/2021

  Endo International plc data will be presented during Cosmetic Bootcamp Summer Event 2021.

• Endo to Announce Second Quarter 2021 Financial Results

  6/24/2021

   Endo International plc (NASDAQ: ENDP) will announce its second–quarter 2021 financial results on August 5, 2021 after the U.S. financial markets close and members of its senior management team will host a conference call and webcast on August 6, 2021 at 7:30am ET before the U.S. financial markets open.

• Tennessee Court Of Appeals Issues Orders Regarding State Court Default Judgment Against Endo

  6/11/2021

  Endo International plc today announced that the Tennessee Court of Appeals recently issued several orders with respect to a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals.

• Endo to Participate at 2021 RBC Capital Markets Global Healthcare Virtual Conference

  5/12/2021

  Endo International plc announced that members of management will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET.

• Endo Reports First-Quarter 2021 Financial Results And Updates 2021 Financial Guidance

  5/6/2021

  Endo International plc reported financial results for the first-quarter ended March 31, 2021.